Scopolamine Market Size
| Study Period | 2021 - 2029 |
| Base Year For Estimation | 2023 |
| CAGR | 6.10 % |
| Fastest Growing Market | Asia-Pacific |
| Largest Market | North America |
| Market Concentration | Medium |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Scopolamine Market Analysis
Over the next few years, the scopolamine market is expected to register a CAGR of about 6.1%.
The COVID-19 pandemic had an extraordinary impact on the scopolamine business. Scopolamine was mostly employed in surgical procedures, and the fall in surgical volume during the pandemic hampered the scopolamine market's growth. For instance, according to an article published in Jama Network in April 2021, an article reported that the frequency of surgical procedures throughout the country experienced a substantial decrease that may persist after the COVID-19 pandemic's initial exponential growth phase. Thus, the surgical procedures were reduced, which decreased the need for scopolamine-related dosage forms as it is used to prevent nausea and vomiting after anesthesia, narcotic pain medicines, and surgery. Thus, initially, the market was severely impacted, but after a few months, it gained its momentum for growth. Over the last two years, the market recovery has been led by the rise in several surgical procedures. For instance, as per the January 2022 report from Euractiv, during the pandemic, 400,000 surgeries were postponed, which considerably increased the number of patients on the waiting list. During the projected period, the market is predicted to have a significant increase in surgeries, which is expected to support market growth in the following years.
The factors that may drive the market are the growing number of surgical procedures, rising healthcare expenditure, and adaptation to scopolamine. According to a July 2021 article published in the Annals of Surgery, nearly nine major surgeries were performed annually in the United States for every 100 older people, and more than one in every seven Medicare beneficiaries underwent a major surgery over five years, representing nearly 5 million surgeries in the United States each year.Thus, a significant number of surgical procedures are performed annually, and it is expected to raise demand for scopolamine to help reduce secretion during surgical operations, thereby boosting the market's growth.
Also, growing treatment trials on scopolamine and its increasing use for the treatment of various diseases In recent times, many studies have reported the use of scopolamine in the treatment of major depressive disorder. For instance, in April 2021, an article published in the International Journal of Psychiatry reported that most available treatment trials of scopolamine have confirmed the rapid onset of antidepressant effects in unipolar and bipolar depression and that scopolamine is used as an alternative treatment option to ketamine in patients with treatment-resistant depression. In addition, the article also reported that seven treatment trials have demonstrated the rapid therapeutic effects of scopolamine in depression, both as monotherapy and as augmentation. Similarly, in August 2022, Southwest Research Institute developed an efficient, fully synthetic method to produce scopolamine, a plant-derived compound used to prevent nausea and vomiting from motion sickness and anesthesia. The accomplishment marks the first time SwRI has fully synthesized a drug compound that is naturally derived from plants. Thus, such research and clinical studies are driving the scopolamine market.
Thus, owing to the above-mentioned factors, such as an increase in the number of surgical procedures and research activities on scopolamine, it is expected to boost the scopolamine market's growth over the forecast period. However, side effects and misuse of scopolamine, and stringent regulatory policies, may slow down its growth during the studied period.
Scopolamine Market Trends
This section covers the major market trends shaping the Scopolamine Market according to our research experts:
Transdermal Patches Segment is Reported to Witness Significant Growth Over the Forecast Period
Transdermal patches are widely used nowadays in the treatment of motion sickness. The transdermal patches are preferred due to ease of use, cost-effectiveness, and availability. The patch is applied to the hairless skin behind the ear and is used to treat motion sickness caused by anesthesia during the surgeries.
One of the significant benefits offered by transdermal scopolamine is that it can be removed when the drug is not needed in the body. Thus, the benefits of transdermal scopolamine may drive the growth of the transdermal patches segment over the forecast period.
Furthermore, the rising number of surgical procedures is expected to boost transdermal patch segment growth. For instance, the Canadian Institutes of Health Information's June 2021 report stated that hip and knee replacements are two of the most common procedures in Canada, with more than 138,000 surgeries a year. It was also reported that 63,496 hip replacements and 75,073 knee replacements were performed in Canada in 2021, and there had been an average increase of about 5% in recent years in the number of knee and hip replacement procedures in the country. As a result of the substantial number of surgical procedures conducted in the country, it is projected that demand for scopolamine patches would expand to lower bodily secretion, and as transdermal patches are more effective than other dosage forms, they would support the segment's growth.
Thus, the above-mentioned factors, such as the benefits of transdermal patches and a growing number of surgeries, are expected to propel the growth of the segment over the forecast period.
North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period
The North American region is anticipated to have a significant market share owing to its well-established healthcare infrastructure and the presence of key market players. Additionally, a growing number of surgeries in the region, coupled with product approval, are anticipated to boost market growth over the forecast period. For instance, in December 2021, Ingenus Pharmaceuticals, LLC (Riconpharma LLC) got approval from the United States Food and Drug Administration (USFDA) to manufacture the generic version of Transderm-Scop (a skin patch). As a result, growing product approval in the region is expected to support the scopolamine market expansion in the North American region.
Further, the growing incidence of cancer cases is causing an increasing demand for cancer-related surgeries, which is increasing the demand for scopolamine. According to a report published by the Government of Canada in November 2021, about 229,200 Canadians were diagnosed with cancer in 2021, and prostate cancer is expected to remain the most diagnosed cancer, accounting for 46% of all cancer diagnoses in 2021. So, as the number of cancer cases rises in the region, so does the number of surgeries related to cancer. This greatly increases the demand for scopolamine, which drives the market.
Additionally, the growing number of surgeries in the region is expected to propel the growth of the market. For instance, the Definitive Healthcare Report published in December 2021 reported that nearly 1 million knee and hip arthroplasties were performed in 2021 alone in the United States. Scopolamine is effectively used in orthopedic surgeries to reduce secretion, thus increasing the demand for scopolamine and thereby boosting the growth of the market.
Thus, due to the aforesaid reasons, such as product approval and a growing number of surgical procedures, the market is expected to witness significant growth in the North American region over the forecast period.
Scopolamine Industry Overview
The scopolamine market is fragmented by nature due to the presence of many global companies operating globally as well as regionally. The competitive landscape includes an analysis of a few international as well as local companies that hold significant market shares. Some of the market players are Pfizer Inc., Baxter International Inc., Myungmoon Pharm Co Ltd., Phytex Australia, Caleb Pharmaceuticals, Inc., GlaxoSmithKline Plc., Centroflora-Cms, Alkaloids of Australia, Perrigo Company Plc., and Novartis International AG, among others.
Scopolamine Market Leaders
-
Pfizer Inc.
-
Baxter International Inc.
-
Myungmoon Pharm Co Ltd
-
Caleb Pharmaceuticals, Inc.
-
C2 Pharma (Centroflora-Cms)
*Disclaimer: Major Players sorted in no particular order
Scopolamine Market News
- July 2022: Bayer HealthCare Pharmaceuticals Inc., Germany, launched its product Transderm-Scop (a skin patch) in the retail as well as online platform markets with a revised formula of 1 mg/72 HR, which got approval from the U.S. Food and Drug Administration.
- March 2022: Athira Pharma, Inc., used scopolamine, a novel small molecule candidate for Alzheimer's, Parkinson's disease dementia, and dementia with Lewy bodies, and ATH-1020, an orally available, brain-penetrant small molecule candidate for neuropsychiatric conditions.
Scopolamine Market Report - Table of Contents
1. INTRODUCTION
- 1.1 Study Assumptions and Market Definition
- 1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
- 4.1 Market Overview
-
4.2 Market Drivers
- 4.2.1 Growing Number of Surgical Procedures due to Chronic Diseases
- 4.2.2 Rising Healthcare Expenditure and Adaptation of Scopolamine
-
4.3 Market Restraints
- 4.3.1 Side Effects and Misuse of Scopolamine
- 4.3.2 Stringent Regulatory Policies
-
4.4 Porter's Five Forces Analysis
- 4.4.1 Threat of New Entrants
- 4.4.2 Bargaining Power of Buyers/Consumers
- 4.4.3 Bargaining Power of Suppliers
- 4.4.4 Threat of Substitute Products
- 4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD million)
-
5.1 By Dosage Form
- 5.1.1 Injectables
- 5.1.2 Tablets
- 5.1.3 Transdermal Patches
- 5.1.4 Other Dosage Forms
-
5.2 By Distribution Channel
- 5.2.1 Hospital Pharmacies
- 5.2.2 Retail Pharmacies
- 5.2.3 Other Distribution Channels
-
5.3 Geography
- 5.3.1 North America
- 5.3.1.1 United States
- 5.3.1.2 Canada
- 5.3.1.3 Mexico
- 5.3.2 Europe
- 5.3.2.1 Germany
- 5.3.2.2 United Kingdom
- 5.3.2.3 France
- 5.3.2.4 Italy
- 5.3.2.5 Spain
- 5.3.2.6 Rest of Europe
- 5.3.3 Asia-Pacific
- 5.3.3.1 China
- 5.3.3.2 Japan
- 5.3.3.3 India
- 5.3.3.4 Australia
- 5.3.3.5 South Korea
- 5.3.3.6 Rest of Asia-Pacific
- 5.3.4 Middle East and Africa
- 5.3.4.1 GCC
- 5.3.4.2 South Africa
- 5.3.4.3 Rest of Middle East and Africa
- 5.3.5 South America
- 5.3.5.1 Brazil
- 5.3.5.2 Argentina
- 5.3.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
-
6.1 Company Profiles
- 6.1.1 Pfizer Inc.
- 6.1.2 Baxter International Inc.
- 6.1.3 Myungmoon Pharm Co Ltd
- 6.1.4 Caleb Pharmaceuticals, Inc.
- 6.1.5 GlaxoSmithKline plc.
- 6.1.6 C2 Pharma (Centroflora-Cms)
- 6.1.7 Alkaloids of Australia
- 6.1.8 Perrigo Company plc
- 6.1.9 Novartis International AG
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
** Subject To AvailablityScopolamine Industry Segmentation
As per the scope of the report, scopolamine is an anticholinergic agent that is used to reduce the secretions of certain organs. It is used in the treatment of motion sickness and postoperative nausea and vomiting. It is sometimes also used before the surgery to decrease secretions such as saliva. The scopolamine market is segmented by dosage form (injectables, tablets, transdermal patches, and others), distribution channel (hospital pharmacies, retail pharmacies, and others), and geography (North America, Europe, Asia-Pacific, the Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers the value (in USD million) for the above segments.
| By Dosage Form | Injectables | |
| Tablets | ||
| Transdermal Patches | ||
| Other Dosage Forms | ||
| By Distribution Channel | Hospital Pharmacies | |
| Retail Pharmacies | ||
| Other Distribution Channels | ||
| Geography | North America | United States |
| Canada | ||
| Mexico | ||
| Geography | Europe | Germany |
| United Kingdom | ||
| France | ||
| Italy | ||
| Spain | ||
| Rest of Europe | ||
| Geography | Asia-Pacific | China |
| Japan | ||
| India | ||
| Australia | ||
| South Korea | ||
| Rest of Asia-Pacific | ||
| Geography | Middle East and Africa | GCC |
| South Africa | ||
| Rest of Middle East and Africa | ||
| Geography | South America | Brazil |
| Argentina | ||
| Rest of South America |
Scopolamine Market Research FAQs
What is the current Scopolamine Market size?
The Scopolamine Market is projected to register a CAGR of 6.10% during the forecast period (2024-2029)
Who are the key players in Scopolamine Market?
Pfizer Inc., Baxter International Inc., Myungmoon Pharm Co Ltd, Caleb Pharmaceuticals, Inc. and C2 Pharma (Centroflora-Cms) are the major companies operating in the Scopolamine Market.
Which is the fastest growing region in Scopolamine Market?
Asia-Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Scopolamine Market?
In 2024, the North America accounts for the largest market share in Scopolamine Market.
What years does this Scopolamine Market cover?
The report covers the Scopolamine Market historical market size for years: 2021, 2022 and 2023. The report also forecasts the Scopolamine Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Scopolamine Industry Report
Statistics for the 2024 Scopolamine market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Scopolamine analysis includes a market forecast outlook 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
